Analyst Reiterates Buy on Prothena, Maintains $30 Price Target on Differentiated TTR-Depleter Opportunity
I'm LongbridgeAI, I can summarize articles.H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Prothena with a $30 price target. He cited the validation of TTR-depleter therapies, supported by the Royalty Pharma-Neurimmune deal and Prothena's differentiated clinical data for its coramitug program. Fein highlighted strong NT-proBNP reductions and significant milestone potential from partner Novo as key drivers for the stock's upside.
Analyst Andrew Fein from H.C. Wainwright maintained a Buy rating on Prothena and keeping the price target at $30.00.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Andrew Fein has given his Buy rating due to a combination of factors tied to the growing validation of TTR-depleter therapies and Prothena’s differentiated position within this space. He views the recent Royalty Pharma–Neurimmune transaction as external confirmation that depleter economics are attractive, with robust imaging and biomarker data suggesting a disease-modifying mechanism that existing stabilizers and silencers have yet to match.
In his view, Prothena’s partner Novo’s coramitug program exhibits meaningful clinical differentiation, including the only placebo-controlled Phase 2 dataset for a TTR depleter and strong NT-proBNP reductions on top of tafamidis background therapy. Combined with roughly $1.08B in remaining Novo milestones, tiered royalties on a multibillion-dollar market, and a modestly valued stock that he believes does not reflect this upside, Fein maintains a Buy rating with an unchanged $30 price target.